Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event
AIM at Melanoma is proud to partner once again with Lilly Pulitzer for their annual Community Giving Event. Now in…
Blog - Melanoma360
04/27/2026
Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event
AIM at Melanoma is proud to partner once again with Lilly Pulitzer for their annual Community Giving Event. Now in…
|
04/19/2026
KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma
OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as…
|
|
04/10/2026
FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients
On April 10, 2026, the U.S. Food and Drug Administration (FDA) issued a decision not to approve the resubmission of…
|
|
04/07/2026
2026 National Sunscreen Partner
We are proud to share that burnd Sunscreen has joined AIM at Melanoma as our 2026 National Sunscreen Partner. This…
|
04/07/2026
Young Adult Cancer & Mental Health
In this episode of Beyond the Clinic: Living Well with Melanoma, host Dr. Samantha Siegel sits down with Dr. Victoria…
|
04/02/2026
Uveal Melanoma Webinar: Part II — Navigating Treatment in the Metastatic Setting
Presented in partnership with Save Your Skin Foundation and Ocumel CanadaOcumel Canada (OC), is powered by Save Your Skin Foundation,…
03/26/2026
Wade Watson, Stage III Melanoma Survivor
A Diagnosis That Changed Everything In early 2021, Wade Watson and his father received life-changing news just weeks apart. His…
|
03/26/2026
Advocates Renew Call for RP1 Approval
As the U.S. Food and Drug Administration approaches a pivotal decision on a potential new treatment for advanced melanoma, patient…
|
03/03/2026
Cancer is More Than a Diagnosis: Mind, Meaning, and Healing
Cancer is often spoken about in terms of diagnosis, treatment plans, and survival rates. But there is a quieter, more…
|
02/19/2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…
|
|
Recent Posts
Apr. 27, 2026
Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event
Apr. 19, 2026
KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma
Apr. 10, 2026
FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients
Apr. 07, 2026
2026 National Sunscreen Partner
Apr. 07, 2026